IBRANCE- palbociclib capsule 
Pfizer Laboratories Div Pfizer Inc


This Patient Information has been approved by the U.S. Food and Drug Administration.Revised: March 2017
IBRANCE® (EYE-brans)


What is the most important information I should know about IBRANCE?

IBRANCE may cause serious side effects, including:

Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your healthcare provider should check your white blood cell counts before and during treatment.

If you develop low white blood cell counts during treatment with IBRANCE, your healthcare provider may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.

See "What are the possible side effects of IBRANCE?" for more information about side effects.

What is IBRANCE?

IBRANCE is a prescription medicine used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) in combination with:

  • an aromatase inhibitor as the first hormonal based therapy in women who have gone through menopause, or
  • fulvestrant in women with disease progression following hormonal therapy.

It is not known if IBRANCE is safe and effective in children.

What should I tell my healthcare provider before taking IBRANCE?

Before you take IBRANCE, tell your healthcare provider if you:

  • have fever, chills, or any other signs or symptoms of infection.
  • have liver or kidney problems.
  • have any other medical conditions.
  • are pregnant, or plan to become pregnant. IBRANCE can harm your unborn baby.
    • Females who are able to become pregnant and who take IBRANCE should use effective birth control during treatment and for at least 3 weeks after stopping IBRANCE.
    • Males who are taking IBRANCE, with female partners who can become pregnant should use effective birth control during treatment with IBRANCE for 3 months after the final dose of IBRANCE.
    • Talk to your healthcare provider about birth control methods that may be right for you during this time.
    • If you become pregnant or think you are pregnant, tell your healthcare provider right away.
  • are breastfeeding or plan to breastfeed. It is not known if IBRANCE passes into your breast milk. You and your healthcare provider should decide if you will take IBRANCE or breastfeed. You should not do both.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. IBRANCE and other medicines may affect each other causing side effects.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take IBRANCE?

  • Take IBRANCE exactly as your healthcare provider tells you.
  • Take IBRANCE with food.
  • Swallow IBRANCE capsules whole. Do not chew, crush or open IBRANCE capsules before swallowing them.
  • Do not take any IBRANCE capsules that are broken, cracked, or that look damaged.
  • Avoid grapefruit and grapefruit products during treatment with IBRANCE. Grapefruit may increase the amount of IBRANCE in your blood.
  • Do not change your dose or stop taking IBRANCE unless your healthcare provider tells you.
  • If you miss a dose of IBRANCE or vomit after taking a dose of IBRANCE, do not take another dose on that day. Take your next dose at your regular time.
  • If you take too much IBRANCE, call your healthcare provider right away or go to the nearest hospital emergency room.

What are the possible side effects of IBRANCE?

IBRANCE may cause serious side effects. See "What is the most important information I should know about IBRANCE?"

Common side effects of IBRANCE when used with either letrozole or fulvestrant include:

  • Low red blood cell counts and low platelet counts are common with IBRANCE. Call your healthcare provider right away if you develop any of these symptoms during treatment:
  • dizziness
  • shortness of breath
  • weakness
  • bleeding or bruising more easily
  • nosebleeds
  • diarrhea
  • hair thinning or hair loss
  • vomiting
  • rash
  • loss of appetite

IBRANCE may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of IBRANCE. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store IBRANCE?

  • Store IBRANCE at 68 °F to 77 °F (20 °C to 25 °C).

Keep IBRANCE and all medicines out of the reach of children.

General information about the safe and effective use of IBRANCE

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IBRANCE for a condition for which it was not prescribed. Do not give IBRANCE to other people, even if they have the same symptoms you have. It may harm them.

If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for more information about IBRANCE that is written for health professionals.

For more information, go to www.IBRANCE.com or call 1-800-438-1985.

What are the ingredients in IBRANCE?

Active ingredient: palbociclib

Inactive ingredients: Microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard gelatin capsule shells.

Light orange, light orange/caramel and caramel opaque capsule shells contain: gelatin, red iron oxide, yellow iron oxide, and titanium dioxide.

Printing ink contains: shellac, titanium dioxide, ammonium hydroxide, propylene glycol, and simethicone.



Revised: 3/2019
Document Id: d33e1bd0-882c-4f38-9e42-0703b2891191
Set id: e0e6412f-50b4-4fd4-9364-62818d121a07
Version: 7
Effective Time: 20190304
Pfizer Laboratories Div Pfizer Inc